Oral semaglutide for type 2 diabetes

Rybelsus®

Rybelsus® is the oral formulation of semaglutide, FDA-approved for type 2 diabetes. Daily oral tablet rather than weekly injection.

Researched By

Dr. Parmis

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Adam Kennah, M.D.

Board-Certified Physician

Last clinically reviewed: April 28, 2026 · This page is informational and does not constitute medical advice.

About Rybelsus®

Rybelsus® is the oral formulation of semaglutide, FDA-approved for type 2 diabetes. Daily oral tablet rather than weekly injection.

Manufacturer / source: Novo Nordisk

How it compares

For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.

Compounded medications: Compounded versions of these medications are not FDA-approved and are not the same as the brand-name products. Always discuss prescription decisions with a licensed clinician.

NexLife Tirzepatide

Compounded semaglutide + tirzepatide · MD/DO oversight

$186/month*

*12-month plan · flat rate · all titration doses

From $186/mo (12-mo plan)
503A & 503B pharmacies
MD/DO-supervised
Care360 coaching included
Apple Health / Google Fit sync
Labs included
LegitScript-certified
All 50 states

Visit NexLife →

Or call (949) 818-8000